IN THE CLAIMS:

Please cancel claims 1-12.

Please amend claim 13 as follows:

13. (Four Times Amended) [The liquid pharmaceutical composition of claim 1] A liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from the group consisting of citric acid, citric acid salt and a combination thereof, wherein the aggregate concentration of all bioavailability enhancing agents is 10-25 mM, said composition being in a form suitable for nasal administration and having a pH of from [about] 3.5 to [about] 3.9.

Please amend claim 14 as follows:

14. (Amended) The liquid pharmaceutical composition of claim [1] 13 having a pH of about 3.7.

Please amend claim 15 as follows:

15. (Four Times Amended) [The liquid pharmaceutical composition of claim 1] A liquid pharmaceutical composition comprising calcitonin or an acid addition salt thereof and a bioavailability enhancing agent selected from the group consisting of citric acid, citric acid salt and a combination thereof, wherein the aggregate concentration of all bioavailability enhancing agents is 10-25 mM, said composition being in a form suitable for nasal administration and having an osmotic pressure of from [about] 250 to [about] 350 mOsm/liter.

Please amend claim 16 as follows:

16. (Amended) The liquid pharmaceutical composition of claim [1] 13 further containing at least 0.1% by weight of polyoxyethylene(20) sorbitan monooleate.

Please amend claim 17 as follows:

17. (Amended) The liquid pharmaceutical composition of claim [1] 13 further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.

Please amend claim 18 as follows:

18. (Amended) A liquid pharmaceutical composition comprising about 2,200 MRC units of salmon calcitonin, [about] 10 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% polyoxyethylene(20) sorbitan monooleate.

Please amend claim 19 as follows:

19. (Amended) A liquid pharmaceutical composition comprising about 2,200 [MIC] MRC units of salmon calcitonin, about 20 mM citric acid, about 0.2% phenylethyl alcohol, about 0.5% benzyl alcohol, and about 0.1% polyoxyethylene(20) sorbitan monooleate.

Please amend claim 20 as follows:

20. (Amended) A method of administering a calcitonin to a subject requiring calcitonin treatment, which method comprises administering to said subject a composition as defined in claim [1] 13 via the nasal route.

Please amend claim 22 as follows:

22. (Amended) A method of improving the stability of a liquid pharmaceutical composition of calcitonin comprising adding citric acid or a salt thereof in a concentration from 10 to [about 50] 25 mM to said composition.

Please amend claim 23 as follows:

23. (Amended) A method of improving the bioavailability or the concentration of plasma calcitonin in a subject following nasal administration of a liquid pharmaceutical composition of

calcitonin, which method comprises adding citric acid or a salt thereof in a concentration from 10 to [about 50] 25 mM to said composition prior to said administration.

Please add new claims 24-45

24. (New) The pharmaceutical composition of claim 15, wherein said citric acid or citric acid salt concentration is 20 mM.

25. (New) The pharmaceutical composition of claim 15, wherein the pH of said composition is from 3.5 to 3.9.

26. (New) The pharmaceutical composition of claim 24, wherein the pH of the composition is from 3.5 to 3.9.

27. (New) The pharmaceutical composition of claim 15, wherein said composition includes aqueous saline.

28. (New) The pharmaceutical composition of claim 15, wherein said composition has a viscosity of less than 0.98 cP.

29. (New) The pharmaceutical composition of claim 15, wherein said composition further contains at least 0.1% by weight of polyoxyethylene(20) sorbitan monooleate.

30. (New) The pharmaceutical composition of claim 15, wherein said composition further contains at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.

31. (New) The pharmaceutical composition of claim 13, wherein said composition includes aqueous saline and has an osmotic pressure from 250 to 350 mOsm/liter.

32. (New) The pharmaceutical composition of claim 13, wherein said composition has a viscosity of less than 0.98 cP.

33. (New) The pharmaceutical composition of claim 15, wherein said calcitonin is salmon calcitonin.

34. (New) The pharmaceutical composition of claim 13, wherein said calcitonin is salmon calcitonin.

35. (New) A method of administering a calcitonin to a subject requiring calcitonin treatment, said method comprising nasally administering to said subject a therapeutically effective amount of the composition of claim 15.

36. (New) A method of administering a calcitonin to a subject requiring calcitonin treatment, said method comprising nasally administering to said subject a therapeutically effective amount of the composition of claim 26.

37. (New) A method of administering a calcitonin to a subject requiring calcitonin treatment, said method comprising nasally administering to said subject a therapeutically effective amount of the composition of claim 31.

38. (New) A method of administering a calcitonin to a subject requiring calcitonin treatment, said method comprising nasally administering to said subject a therapeutically effective amount of the composition of claim 32.

39. (New) A method of administering a calcitonin to a subject requiring calcitonin treatment, said method comprising nasally administering to said subject a therapeutically effective amount of the composition of claim 33.

40. (New) A method of administering a calcitonin to a subject requiring calcitonin treatment, said method comprising nasally administering to said subject a therapeutically effective amount of the composition of claim 34.

41. (New) The method of claim 22, wherein the pH of said pharmaceutical composition is from 3.5 to 3.9.

42. (New) The method of claim 23, wherein the pH of said pharmaceutical composition is from 3.5 to 3.9.

43. (New) The method of claim 22, wherein said composition includes an aqueous saline and has an osmotic pressure from 250 to 350 mOsm/liter.

44. (New) The method of claim 23, wherein said composition includes an aqueous saline and has an osmotic pressure from 250 to 350 mOsm/liter.

45. (New) The liquid pharmaceutical composition of claim 16, further containing at least one preservative selected from the group consisting of benzyl alcohol, phenylethyl alcohol, methyl parabens, ethyl parabens, propyl parabens and butyl parabens.